Daniel Gaudet
Daniel Gaudet
ecogene21 Biocluster and dept of Medicine Université de Montréal
Verified email at umontreal.ca
TitleCited byYear
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
D Altshuler, JN Hirschhorn, M Klannemark, CM Lindgren, MC Vohl, ...
Nature genetics 26 (1), 76, 2000
Simvastatin with or without ezetimibe in familial hypercholesterolemia
JJP Kastelein, F Akdim, ESG Stroes, AH Zwinderman, ML Bots, ...
New England Journal of Medicine 358 (14), 1431-1443, 2008
Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?
I Lemieux, A Pascot, C Couillard, B Lamarche, A Tchernof, N Alméras, ...
Circulation 102 (2), 179-184, 2000
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease
JD Rioux, MJ Daly, MS Silverberg, K Lindblad, H Steinhart, Z Cohen, ...
Nature genetics 29 (2), 223, 2001
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised …
FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, ...
The Lancet 375 (9719), 998-1006, 2010
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on …
EA Stein, D Gipe, J Bergeron, D Gaudet, R Weiss, R Dufour, R Wu, ...
The Lancet 380 (9836), 29-36, 2012
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
FJ Raal, EA Stein, R Dufour, T Turner, F Civeira, L Burgess, G Langslet, ...
The Lancet 385 (9965), 331-340, 2015
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
M Cuchel, EA Meagher, H du Toit Theron, DJ Blom, AD Marais, ...
the Lancet 381 (9860), 40-46, 2013
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia
C Gagné, D Gaudet, E Bruckert
Circulation 105 (21), 2469-2475, 2002
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility
AC Villani, M Lemire, G Fortin, E Louis, MS Silverberg, C Collette, N Baba, ...
Nature genetics 41 (1), 71, 2009
Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region
JC Florez, N Burtt, PIW De Bakker, P Almgren, T Tuomi, J Holmkvist, ...
Diabetes 53 (5), 1360-1368, 2004
Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia
D Gaudet, VJ Alexander, BF Baker, D Brisson, K Tremblay, W Singleton, ...
New England Journal of Medicine 373 (5), 438-447, 2015
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
D Gaudet, J Méthot, S Déry, D Brisson, C Essiembre, G Tremblay, ...
Gene therapy 20 (4), 361, 2013
Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess …
EA Stein, R Dufour, C Gagne, D Gaudet, C East, JM Donovan, W Chin, ...
Circulation 126 (19), 2283-2292, 2012
Targeting APOC3 in the familial chylomicronemia syndrome
D Gaudet, D Brisson, K Tremblay, VJ Alexander, W Singleton, SG Hughes, ...
New England Journal of Medicine 371 (23), 2200-2206, 2014
Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes
W Winckler, MN Weedon, RR Graham, SA McCarroll, S Purcell, ...
Diabetes 56 (3), 685-693, 2007
Molecular scanning of the human PPARα gene: association of the L162V mutation with hyperapobetalipoproteinemia
MC Vohl, P Lepage, D Gaudet, CG Brewer, C Bétard, P Perron, G Houde, ...
Journal of Lipid Research 41 (6), 945-952, 2000
5′ flanking variants of resistin are associated with obesity
JC Engert, MC Vohl, SM Williams, P Lepage, JC Loredo-Osti, J Faith, ...
Diabetes 51 (5), 1629-1634, 2002
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino Sr, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial
H Bays, D Gaudet, R Weiss, JL Ruiz, GF Watts, I Gouni-Berthold, ...
The Journal of Clinical Endocrinology & Metabolism 100 (8), 3140-3148, 2015
The system can't perform the operation now. Try again later.
Articles 1–20